Abaloparatide - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for abaloparatide and what is the scope of patent protection?
Abaloparatide
is the generic ingredient in one branded drug marketed by Radius and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Abaloparatide has fifty-three patent family members in twenty-eight countries.
One supplier is listed for this compound.
Summary for abaloparatide
International Patents: | 53 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 12 |
Clinical Trials: | 14 |
Patent Applications: | 128 |
Drug Prices: | Drug price trends for abaloparatide |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for abaloparatide |
What excipients (inactive ingredients) are in abaloparatide? | abaloparatide excipients list |
DailyMed Link: | abaloparatide at DailyMed |
Recent Clinical Trials for abaloparatide
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Daniel Horwitz | Phase 4 |
Johns Hopkins University | Phase 2 |
University of Vermont | Phase 2 |
Pharmacology for abaloparatide
Drug Class | Parathyroid Hormone-Related Peptide Analog |
Anatomical Therapeutic Chemical (ATC) Classes for abaloparatide
Paragraph IV (Patent) Challenges for ABALOPARATIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TYMLOS | Subcutaneous Injection | abaloparatide | 3.12 mg/1.56 mL | 208743 | 1 | 2022-06-21 |
US Patents and Regulatory Information for abaloparatide
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Radius | TYMLOS | abaloparatide | SOLUTION;SUBCUTANEOUS | 208743-001 | Apr 28, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for abaloparatide
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Radius Health Ireland Ltd | Eladynos | abaloparatide | EMEA/H/C/004157 Treatment of osteoporosis. |
Refused | no | no | no | 2019-01-07 | |
Theramex Ireland Limited | Eladynos | abaloparatide | EMEA/H/C/005928 Treatment of osteoporosis in postmenopausal women at increased risk of fracture. |
Authorised | no | no | no | 2022-12-12 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for abaloparatide
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hong Kong | 1214181 | 包含 的穩定組合物及其用途 (A STABLE COMPOSITION COMPRISING PTHRP AND USES THEREOF PTHRP) | ⤷ Sign Up |
Slovenia | 2957278 | ⤷ Sign Up | |
European Patent Office | 3908605 | PROCÉDÉS DE DÉTECTION D'ANTICORPS DE NEUTRALISATION DIRIGÉS CONTRE L'HORMONE PARATHYROÏDE (PTH) ET ANALOGUE DE PEPTIDE LIÉ À L'HORMONE PARATHYROÏDE (PTHRP) (METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG) | ⤷ Sign Up |
Canada | 3122231 | PROCEDES DE DETECTION D'ANTICORPS DE NEUTRALISATION DIRIGES CONTRE L'HORMONE PARATHYROIDE (PTH) ET ANALOGUE DE PEPTIDE LIE A L'HORMONE PARATHYROIDE (PTHRP) (METHODS FOR DETECTING NEUTRALIZING ANTIBODIES TO PARATHYROID HORMONE (PTH) AND PARATHYROID HORMONE-RELATED PEPTIDE (PTHRP) ANALOG) | ⤷ Sign Up |
Australia | 2007322334 | Method of drug delivery for bone anabolic protein | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for abaloparatide
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2073789 | 2390018-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: ABALOPARATIDE; REG. NO/DATE: EU/1/22/1706 20221213 |
2073789 | 2023C/523 | Belgium | ⤷ Sign Up | PRODUCT NAME: ABALOPARATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1706 20221213 |
2073789 | 23/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 (MITTEILUNG) 20221213 |
2073789 | CA 2023 00019 | Denmark | ⤷ Sign Up | PRODUCT NAME: ABALOPARATID; REG. NO/DATE: EU/1/22/1706 20221213 |
2073789 | 122023000031 | Germany | ⤷ Sign Up | PRODUCT NAME: ABALOPARATID; REGISTRATION NO/DATE: EU/1/22/1706 20221212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.